<DOC>
	<DOCNO>NCT02149706</DOCNO>
	<brief_summary>Multi-center , randomize , double-blind , placebo-controlled , two arm parallel design study NeuroVax™ v . Incomplete Freund 's Adjuvant ( I F A ) placebo . 150 subject Secondary Progressive SPMS .</brief_summary>
	<brief_title>A Study NeuroVax™ , Novel Therapeutic TCR Peptide Vaccine SPMS Multiple Sclerosis</brief_title>
	<detailed_description>The primary objective compare treatment group Measures neurologic disability EDSS score .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>Ages Eligible Study : 18 Years 70 Years Genders Eligible Study : Both Accepts Healthy Volunteers : No Criteria Subject 18 70 year age , inclusive . Definite MS revise McDonald criterion ( 2005 ) ( Appendix A ) , Secondary Progressive course . Expanded Disability Status Scale ( EDSS ) &gt; =score 3.5 ( Appendix B ) . Two document clinical relapse MS precede 24 month OR one document clinical relapse MS precede 1 2 month prior screen . Laboratory value within follow limit : Creatinine 1 . 5 x high normal . Hemoglobin Subjects currently prescribe Campath Lemtrada</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Secondary Progress Multiple Sclerosis</keyword>
	<keyword>SPMS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>NeuroVax</keyword>
</DOC>